Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

Journal of Molecular Neuroscience

Volumn 54, Issue 3, 2014, Pages 512-525

  Jimeno, Rebeca ^a   Leceta, Javier ^a   Martínez, Carmen ^a   Gutiérrez Cañas, Irene ^a   Carrión, Mar ^a   Pérez García, Selene ^a   Garín, Marina ^b   Mellado, Mario ^c   Gomariz, Rosa P ^a   Juarranz, Yasmina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CIEMAT   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Th differentiation; Th17; VIP; VPAC receptors

Indexed keywords

IL23R PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RORA PROTEIN, HUMAN; RORC PROTEIN, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, RAT; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHENOTYPE; TH17 CELL;

CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-17; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 1; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PHENOTYPE; RECEPTORS, INTERLEUKIN; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; STAT3 TRANSCRIPTION FACTOR; TH17 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84939892554     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0318-3     Document Type: Article

References (50)

1. Abad C, Juarranz Y, Martínez C, Arranz A, Rosignoli F, García-Gómez M et al (2005) cDNA array analysis of cytokines, chemokines and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 11:674–684
2. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A et al (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639–646
3. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB et al (2007) TH17 cells contribute to uveitis and seleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13:711–718
4. Arranz A, Abad A, Juarranz Y, Leceta J, Martínez C, Gomariz RP (2008) Vasoactive intestinal peptide as a healing mediator in Crohn’s disease. Neuroimmunomodulation 15:46–53
5. Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I (2011) Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur J Pharmacol 670:186–194
6. Beriou G, Brandshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T et al (2010) TGF beta induces IL-9 production from human Th17 cells. J Immunol 185:46–54
7. Bi Y, Yang R (2012) Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions. Scand J Immunol 75:543–552
8. Calafat M, Larocca L, Roca V, Hauk V, Pregi N, Nessi A et al (2009) Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 11:R53
9. Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P et al (2012) Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J 26:2060–2071
10. Chen Z, O’Shea JJ (2008) Regulation of IL17 production in human lymphocytes. Cytokine 41:71–78
11. Couvineau A, Laburthe M (2012) VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 166:42–50
12. Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10:479–489
13. Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68:27–38
14. Delgado M, Abad C, Martínez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563–568
15. Ding W, Manni M, Stohl LL, Zhou XK, Wagner JA, Granstein RD (2012) Pituitary adenylate cyclise-activating polypeptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol 4:901–911
16. Dorsam GP, Benton K, Failing J, Batra S (2011) Vasoactive intestinal peptide signalling axis in human leukemia. World J Biol Chem 2:146–160
17. Ganjalikhani M, Ghaedi K, Ahdalib A, Hosseini M, Rezaei A (2011) Optimization of human Th17 cell differentiation in vitro: evaluating different polarization factors. In Vitro Cell Dev Biol Anim 47:581–592
18. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ (2011) T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 39:395–401
19. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martínez C (2006) VIP-PACAP system in immunity: new insights for multitarget theraphy. Ann N Y Acad Sci 1070:51–74
20. Gomariz RP, Gutiérrez-Cañas I, Arranz A, Carrión M, Juarranz Y, Leceta J et al (2010) Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Des 16:1063–1080
21. Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (1997) In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18:1555–1560
22. Graeber KE, Olsen NJ (2012) Th17 cell cytokine secretion profile in host defense and autoimmunity. Inflamm Res 61:87–96
23. Gutiérrez-Cañas I, Juarranz Y, Santiago B, Martínez C, Gomariz RP, Pablos JL et al (2008) Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid artritis. Brain Behav Immun 22:312–317
24. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR et al (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4–17
25. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O’Shea JJ (2010) Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21:425–434
26. Hirota K, Ahlfors H, Duarte JH, Stockinger B (2012) Regulation and function of innate and adaptive interleukin-17 producing cells. EMBO Rep 13:113–120
27. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J (2010) New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88:734–745
28. Jimeno R, Leceta J, Martínez C, Gutiérrez-Cañas I, Pérez-García S, Carrión M et al (2011) Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol Cell Biol 90:178–186
29. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58:1086–1095
30. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517
31. Leceta J, Gomariz RP, Martinez C, Carrión M, Arranz A, Juarranz Y (2007) Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 14:134–138
32. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO et al (2008) Late developmental plasticity in the T helper 17 lineage. Immunity 30:92–107
33. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A et al (2012) Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13:991–999
34. Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T et al (2010) IFNγ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol 40:3017–3027
35. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP et al (2006) Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren’s syndrome. Ann Rheum Dis 65:195–200
36. Marwaha AK, Leung NJ, McMurchy AN, Leving MK (2012) TH17 cells in autoimmunity and immunodeficiency: protective or pathogenic? Front Immunol 3:129
37. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T et al (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8:1390–1397
38. Murphy KM, Stockinger B (2010) Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 11:674–680
39. O’Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327:1098–1102
40. Santarlasci V, Maggi L, Capone M, Querci V, Beltrame L, Cavalieri D et al (2012) Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity 36:201–214
41. Smalley SG, Barrow PA, Foster N (2009) Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 157:225–234
42. Sundrud MS, Trivigno C (2013) Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 25:263–272
43. Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC et al (2012) Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim Biophys Acta 1823:1676–1685
44. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC et al (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:106–109
45. Vomhof-Dekrey EE, Dorsam GP (2008) Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells. Brain Behav Immun 22:1024–1031
46. Yadav M, Rosenbaum J, Goetzl EJ (2008) Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 180:2772–2776
47. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y et al (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28:29–39
48. Zhu J, Paul WE (2008) CD4 T cells: fates, functions and faults. Blood 112:1557–1569
49. Zhu J, Paul WE (2010) Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 238:247–262
50. Zuñiga LA, Jain R, Haines C, Cua DJ (2013) Th17 cell development from the cradle to the grave. Immunol Rev 252:78–88